stoxline Quote Chart Rank Option Currency Glossary
Sunshine Biopharma, Inc. (SBFM)
0.3397  -0.001 (-0.38%)    07-12 14:05
Open: 0.3481
High: 0.3496
Volume: 448,106
Pre. Close: 0.341
Low: 0.332
Market Cap: 8(M)
Technical analysis
2024-07-12 1:53:53 PM
Short term     
Mid term     
Targets 6-month :  0.53 1-year :  0.66
Resists First :  0.45 Second :  0.56
Pivot price 0.36
Supports First :  0.28 Second :  0.23
MAs MA(5) :  0.34 MA(20) :  0.36
MA(100) :  3.15 MA(250) :  20.82
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  30.5 D(3) :  33.9
RSI RSI(14): 35.8
52-week High :  64.5 Low :  0.28
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SBFM ] has closed above bottom band by 36.3%. Bollinger Bands are 97.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 45 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.36 - 0.36 0.36 - 0.36
Low: 0.33 - 0.33 0.33 - 0.33
Close: 0.34 - 0.34 0.34 - 0.34
Company Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

Headline News

Tue, 21 May 2024
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54% - Yahoo Finance

Fri, 12 Apr 2024
Sunshine Biopharma announces reverse stock split -

Tue, 02 Apr 2024
Sunshine Biopharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Mon, 01 Apr 2024
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 - Yahoo Finance

Thu, 14 Mar 2024
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St

Mon, 04 Mar 2024
Why Is Sunshine Biopharma (SBFM) Stock Down 17% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 19 (M)
Shares Float 19 (M)
Held by Insiders 0.5 (%)
Held by Institutions 0.5 (%)
Shares Short 1,570 (K)
Shares Short P.Month 176 (K)
Stock Financials
EPS -13.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 24.94
Profit Margin -15.3 %
Operating Margin -18 %
Return on Assets (ttm) -9.2 %
Return on Equity (ttm) -18.5 %
Qtrly Rev. Growth 54 %
Gross Profit (p.s.) 0
Sales Per Share 1.41
EBITDA (p.s.) -0.22
Qtrly Earnings Growth 0 %
Operating Cash Flow -10 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.03
PEG Ratio 0
Price to Book value 0.01
Price to Sales 0.24
Price to Cash Flow -0.65
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android